PURPOSE: To provide preliminary information about the safety and efficacy of plasma rich in growth factors (PRGF) in the treatment of evaporative dry eye (EDE) and analyze the influence of certain variables on treatment outcomes. METHODS: This retrospective study included patients with EDE treated between January 2011 and December 2013. Outcome measures including signs and symptoms of the disease were evaluated before and after treatment. The influence of some of the patient's clinical variables on results was assessed. Safety assessment was also performed. RESULTS: Eighty-three patients with a total of 156 eyes were evaluated. Statistically significant reductions in the Ocular Surface Disease Index (38.2%), best-corrected visual acuity (27.4%), Visual Analogue Scale scores for frequency (32%) and severity (34%), and a significant improvement in the Schirmer test scores (177.5%) were observed (p < 0.05). The results were stratified according to the identified potential effect modifiers. Only four adverse events were reported. All of them were mild and resolved within a few days. CONCLUSIONS: Results suggest that PRGF eye drops could be a safe and effective treatment in reducing EDE signs and symptoms. When treating patients, the possible influence of some clinical variables must be taken into account.
PURPOSE: To provide preliminary information about the safety and efficacy of plasma rich in growth factors (PRGF) in the treatment of evaporative dry eye (EDE) and analyze the influence of certain variables on treatment outcomes. METHODS: This retrospective study included patients with EDE treated between January 2011 and December 2013. Outcome measures including signs and symptoms of the disease were evaluated before and after treatment. The influence of some of the patient's clinical variables on results was assessed. Safety assessment was also performed. RESULTS: Eighty-three patients with a total of 156 eyes were evaluated. Statistically significant reductions in the Ocular Surface Disease Index (38.2%), best-corrected visual acuity (27.4%), Visual Analogue Scale scores for frequency (32%) and severity (34%), and a significant improvement in the Schirmer test scores (177.5%) were observed (p < 0.05). The results were stratified according to the identified potential effect modifiers. Only four adverse events were reported. All of them were mild and resolved within a few days. CONCLUSIONS: Results suggest that PRGF eye drops could be a safe and effective treatment in reducing EDE signs and symptoms. When treating patients, the possible influence of some clinical variables must be taken into account.
Authors: Ronald Mauricio Sanchez-Avila; Jesus Merayo-Lloves; Ana Cristina Riestra; Luis Fernandez-Vega Cueto; Eduardo Anitua; Leire Begoña; Francisco Muruzabal; Gorka Orive Journal: Int Ophthalmol Date: 2017-06-15 Impact factor: 2.031
Authors: Antonio J Villatoro; Viviana Fernández; Silvia Claros; Cristina Alcoholado; Manuel Cifuentes; Jesús Merayo-Lloves; José A Andrades; José Becerra Journal: Int J Mol Sci Date: 2017-10-28 Impact factor: 5.923
Authors: Jorge L Alio; Alejandra E Rodriguez; Renan Ferreira-Oliveira; Dominika Wróbel-Dudzińska; Ahmed A Abdelghany Journal: Ophthalmol Ther Date: 2017-08-08
Authors: Eduardo Anitua; María de la Fuente; Francisco Muruzabal; Ronald Mauricio Sánchez-Ávila; Jesús Merayo-Lloves; Mikel Azkargorta; Felix Elortza; Gorka Orive Journal: PLoS One Date: 2018-10-12 Impact factor: 3.240
Authors: Borja de la Sen-Corcuera; Jesús Montero-Iruzubieta; Ronald M Sánchez-Ávila; Gorka Orive; Eduardo Anitua; Manuel Caro-Magdaleno; Jesús Merayo-Lloves Journal: Clin Ophthalmol Date: 2020-06-17
Authors: Eduardo Anitua; Francisco Muruzabal; Ander Pino; Roberto Prado; Mikel Azkargorta; Felix Elortza; Jesús Merayo-Lloves Journal: Int J Mol Sci Date: 2021-11-10 Impact factor: 5.923
Authors: Ronald M Sánchez-Avila; Jesus Merayo-Lloves; Maria Laura Fernández; Luis Alberto Rodríguez-Gutiérrez; Pedro Pablo Rodríguez-Calvo; Andres Fernández-Vega Cueto; Francisco Muruzabal; Gorka Orive; Eduardo Anitua Journal: Int Med Case Rep J Date: 2018-05-01
Authors: Eduardo Anitua; María de la Fuente; Ignacio Alcalde; Cristina Sanchez; Jesús Merayo-Lloves; Francisco Muruzabal Journal: Transl Vis Sci Technol Date: 2020-06-25 Impact factor: 3.283